ACRS•benzinga•
Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy
Summary
HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and asthma.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 23, 2024 by benzinga